Pascal Deschatelets - Feb 21, 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Stock symbol
APLS
Transactions as of
Feb 21, 2023
Transactions value $
-$69,908
Form type
4
Date filed
2/22/2023, 05:44 AM
Previous filing
Feb 14, 2023
Next filing
Mar 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +9.89K +0.98% $0.00 1.02M Feb 21, 2023 Direct F1
transaction APLS Common Stock Tax liability -$69.9K -1.2K -0.12% $58.50 1.01M Feb 21, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $0 +14K $0.00 14K Feb 21, 2023 Common Stock 14K $35.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted performance-based restricted stock units ("PRSUs") on January 21, 2022, the vesting of which was subject to the attainment of each of the following events: (i) the submission of a new drug application ("NDA") for intravitreal pegcetacoplan with the U.S. Food and Drug Administration ("FDA") for the treatment of geographic atrophy secondary to age-related macular degeneration in the second quarter of 2022; (ii) the acceptance of such NDA with priority review by the FDA; and (iii) receipt of approval of the NDA by the FDA by March 15, 2023 (collectively, the "2022 Performance Condition"). On February 21, 2023, the Compensation Committee determined that the 2022 Performance Condition had been achieved, resulting in the vesting of 2,471 shares of common stock, representing 25% of the shares underlying the PRSUs. The remaining shares underlying the PRSUs vest as to 25% on each anniversary of the grant date thereafter, subject to continued service.
F2 Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of PRSUs.
F3 The Reporting Person was granted performance-based stock options on January 21, 2022, the vesting of which was subject to the attainment of the 2022 Performance Condition. On February 21, 2023, the Compensation Committee determined that the 2022 Performance Condition had been achieved, resulting in the vesting of 25% of the shares underlying the option. The remaining shares underlying the option vest in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.